Cargando…
New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases
Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) r...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816708/ https://www.ncbi.nlm.nih.gov/pubmed/24276320 http://dx.doi.org/10.3390/ph6070881 |
_version_ | 1782477977190137856 |
---|---|
author | Koenig, Olivia Walker, Tobias Perle, Nadja Zech, Almuth Neumann, Bernd Schlensak, Christian Wendel, Hans-Peter Nolte, Andrea |
author_facet | Koenig, Olivia Walker, Tobias Perle, Nadja Zech, Almuth Neumann, Bernd Schlensak, Christian Wendel, Hans-Peter Nolte, Andrea |
author_sort | Koenig, Olivia |
collection | PubMed |
description | Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future. |
format | Online Article Text |
id | pubmed-3816708 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-38167082013-11-14 New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases Koenig, Olivia Walker, Tobias Perle, Nadja Zech, Almuth Neumann, Bernd Schlensak, Christian Wendel, Hans-Peter Nolte, Andrea Pharmaceuticals (Basel) Review Coronary heart disease (CHD), mainly caused by atherosclerosis, represents the single leading cause of death in industrialized countries. Besides the classical interventional therapies new applications for treatment of vascular wall pathologies are appearing on the horizon. RNA interference (RNAi) represents a novel therapeutic strategy due to sequence-specific gene-silencing through the use of small interfering RNA (siRNA). The modulation of gene expression by short RNAs provides a powerful tool to theoretically silence any disease-related or disease-promoting gene of interest. In this review we outline the RNAi mechanisms, the currently used delivery systems and their possible applications to the cardiovascular system. Especially, the optimization of the targeting and transfection procedures could enhance the efficiency of siRNA delivery drastically and might open the way to clinical applicability. The new findings of the last years may show the techniques to new innovative therapies and could probably play an important role in treating CHD in the future. MDPI 2013-07-19 /pmc/articles/PMC3816708/ /pubmed/24276320 http://dx.doi.org/10.3390/ph6070881 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/). |
spellingShingle | Review Koenig, Olivia Walker, Tobias Perle, Nadja Zech, Almuth Neumann, Bernd Schlensak, Christian Wendel, Hans-Peter Nolte, Andrea New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases |
title | New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases |
title_full | New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases |
title_fullStr | New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases |
title_full_unstemmed | New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases |
title_short | New Aspects of Gene-Silencing for the Treatment of Cardiovascular Diseases |
title_sort | new aspects of gene-silencing for the treatment of cardiovascular diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3816708/ https://www.ncbi.nlm.nih.gov/pubmed/24276320 http://dx.doi.org/10.3390/ph6070881 |
work_keys_str_mv | AT koenigolivia newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT walkertobias newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT perlenadja newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT zechalmuth newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT neumannbernd newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT schlensakchristian newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT wendelhanspeter newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases AT nolteandrea newaspectsofgenesilencingforthetreatmentofcardiovasculardiseases |